Literature DB >> 20042964

Surgery significantly improves survival in patients with chordoma.

Muhammad Umar Jawad1, Sean P Scully.   

Abstract

STUDY
DESIGN: Retrospective database review using Surveillance, Epidemiology, and End Results database, National Cancer Institute.
OBJECTIVE: To determine current treatment outcomes and demographic characteristics and to define the prognostic factors and impact of surgery on survival. SUMMARY OF THE BACKGROUND DATA: Rarity of the disease has limited the number of population-based studies addressing the issues of prognostic factors and the current treatment outcomes.
METHODS: A total of 962 patients with chordoma, diagnosed between 1973 and 2005, were identified in the Surveillance, Epidemiology, and End Results database. Patient demographics and clinical characteristics, incidence, year of diagnosis, location, size and stage at diagnosis, treatment(s), and survival were extracted. Kaplan-Meier, log-rank, and Cox regression were used to analyze the significance of prognostic factors.
RESULTS: Race specific incidence per 100,000 persons in 2005 shows whites to have the highest (0.473) incidence, followed by Asians/Pacific Islanders (0.091), and Afro-Americans (zero), respectively. The incidence difference between whites and Afro-Americans over time is statistically significant (P < 0.001). The age adjusted incidence reveals a peak in eighth decade of life. Survival was not impacted by race. Age category <59, Hispanic ethnicity, size <8 cm, and surgical resection were all independent predictors of better overall survival. Analysis revealed that survival outcomes were very similar in patients with "in-operable disease" and those in which "surgery was recommended but not performed" suggesting that benefits of resection cannot be solely attributed to selection bias.
CONCLUSION: With high local recurrence rates and the significant functional morbidity associated with surgical resections, clinicians are left wondering if surgery constitutes an appropriate treatment option. Our study clearly demonstrates that surgery significantly improves the overall survival for patients with chordoma. We have further identified age <59 and size of primary tumor <8 cm as important prognostic factors determining the outcome with substantial statistical significance.

Entities:  

Mesh:

Year:  2010        PMID: 20042964     DOI: 10.1097/BRS.0b013e3181b44387

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  13 in total

1.  Comparing operative exposures of the le fort I osteotomy and the expanded endoscopic endonasal approach to the clivus.

Authors:  Christopher I Sanders Taylor; Almaz Kurbanov; Lee A Zimmer; Jeffrey T Keller; Philip V Theodosopoulos
Journal:  J Neurol Surg B Skull Base       Date:  2014-09-02

2.  Low dose radiotherapy is associated with local complications but not disease control in sacral chordoma.

Authors:  Matthew T Houdek; Peter S Rose; Mario Hevesi; Joseph H Schwab; Anthony M Griffin; John H Healey; Ivy A Petersen; Thomas F DeLaney; Peter W Chung; Michael J Yaszemski; Jay S Wunder; Francis J Hornicek; Patrick J Boland; Franklin H Sim; Peter C Ferguson
Journal:  J Surg Oncol       Date:  2019-02-07       Impact factor: 3.454

Review 3.  Variables affecting functional improvement in chordoma patients admitted to an inpatient rehabilitation facility: A retrospective review.

Authors:  Sasha E Knowlton; Richard Goldstein; Kevin C O'Connor; Joseph Schwab; Francis Hornicek; Ross Zafonte
Journal:  J Spinal Cord Med       Date:  2017-05-02       Impact factor: 1.985

Review 4.  The biological basis for modern treatment of chordoma.

Authors:  Roberto Jose Diaz; Michael D Cusimano
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

5.  Extensive lumbar chordoma and unique reconstructive approach.

Authors:  Praveenan Sivabalan; Jane Li; Ralph J Mobbs
Journal:  Eur Spine J       Date:  2011-04-10       Impact factor: 3.134

6.  Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival.

Authors:  S H Bakker; W C H Jacobs; W Pondaag; H Gelderblom; R A Nout; P D S Dijkstra; W C Peul; C L A Vleggeert-Lankamp
Journal:  Eur Spine J       Date:  2018-09-15       Impact factor: 3.134

7.  Surgical and Functional Outcomes of En Bloc Resection of Sacral Chordoma: a Retrospective Analysis.

Authors:  Rohit Sharma; Debashish Mukherjee; Amiy Arnav; R Shankaran; Varun Kumar Agarwal
Journal:  Indian J Surg Oncol       Date:  2021-11-19

Review 8.  Novel targeted therapies in chordoma: an update.

Authors:  Salvatore Di Maio; Stephen Yip; Gmaan A Al Zhrani; Fahad E Alotaibi; Abdulrahman Al Turki; Esther Kong; Robert C Rostomily
Journal:  Ther Clin Risk Manag       Date:  2015-05-26       Impact factor: 2.423

9.  The unresolved case of sacral chordoma: from misdiagnosis to challenging surgery and medical therapy resistance.

Authors:  Fabio Garofalo; Dimitrios Christoforidis; Pietro G di Summa; Béatrice Gay; Stéphane Cherix; Wassim Raffoul; Nicolas Demartines; Maurice Matter
Journal:  Ann Coloproctol       Date:  2014-06-23

10.  C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study.

Authors:  Gerhard Martin Hobusch; Florian Bodner; Sonja Walzer; Rodrig Marculescu; Philipp T Funovics; Irene Sulzbacher; Reinhard Windhager; Joannis Panotopoulos
Journal:  World J Surg Oncol       Date:  2016-04-18       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.